X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (26354) 26354
Book Chapter (86) 86
Dissertation (39) 39
Publication (26) 26
Conference Proceeding (24) 24
Magazine Article (22) 22
Web Resource (10) 10
Book / eBook (4) 4
Newspaper Article (4) 4
Trade Publication Article (3) 3
Book Review (2) 2
Newsletter (2) 2
Paper (2) 2
Reference (2) 2
Government Document (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
bevacizumab (22213) 22213
humans (17479) 17479
female (10305) 10305
oncology (9071) 9071
male (8779) 8779
middle aged (7410) 7410
aged (6991) 6991
ophthalmology (6426) 6426
chemotherapy (5486) 5486
cancer (4936) 4936
angiogenesis inhibitors - therapeutic use (4929) 4929
adult (4899) 4899
treatment outcome (4696) 4696
endothelial growth-factor (4280) 4280
vascular endothelial growth factor (4278) 4278
antibodies, monoclonal, humanized (4161) 4161
vascular endothelial growth factor a - antagonists & inhibitors (4095) 4095
angiogenesis (3784) 3784
antineoplastic combined chemotherapy protocols - therapeutic use (3682) 3682
ranibizumab (3243) 3243
aged, 80 and over (3165) 3165
care and treatment (3026) 3026
therapy (3023) 3023
angiogenesis inhibitors - administration & dosage (3011) 3011
retrospective studies (2797) 2797
animals (2695) 2695
intravitreal injections (2678) 2678
metastasis (2472) 2472
antibodies, monoclonal - therapeutic use (2456) 2456
macular degeneration (2398) 2398
survival (2392) 2392
colorectal cancer (2319) 2319
vegf (2138) 2138
antibodies, monoclonal - administration & dosage (2105) 2105
medicine & public health (2088) 2088
antibodies, monoclonal, humanized - administration & dosage (2057) 2057
antibodies, monoclonal, humanized - therapeutic use (2026) 2026
research (1982) 1982
surgery (1960) 1960
trial (1937) 1937
follow-up studies (1930) 1930
colorectal neoplasms - drug therapy (1908) 1908
antineoplastic agents - therapeutic use (1904) 1904
prognosis (1900) 1900
patients (1862) 1862
pharmacology & pharmacy (1806) 1806
tumors (1800) 1800
tomography, optical coherence (1783) 1783
disease-free survival (1770) 1770
analysis (1738) 1738
drug therapy (1733) 1733
angiogenesis inhibitors - adverse effects (1674) 1674
eye diseases (1660) 1660
angiogenesis inhibitors (1638) 1638
clinical trials (1600) 1600
expression (1586) 1586
fluorescein angiography (1568) 1568
intravitreal bevacizumab (1560) 1560
colorectal neoplasms - pathology (1526) 1526
combination (1517) 1517
bevacizumab - administration & dosage (1490) 1490
visual acuity (1448) 1448
bevacizumab - therapeutic use (1428) 1428
prospective studies (1425) 1425
fluorouracil (1416) 1416
oxaliplatin (1398) 1398
antineoplastic combined chemotherapy protocols - adverse effects (1354) 1354
genetic structures (1343) 1343
cetuximab (1337) 1337
paclitaxel (1334) 1334
1st-line treatment (1316) 1316
antineoplastic agents (1287) 1287
mice (1284) 1284
cancer therapies (1273) 1273
efficacy (1252) 1252
neovascularization (1252) 1252
lung neoplasms - drug therapy (1249) 1249
health aspects (1242) 1242
visual acuity - physiology (1227) 1227
irinotecan (1223) 1223
avastin (1212) 1212
antimitotic agents (1210) 1210
hematology, oncology and palliative medicine (1208) 1208
leucovorin (1192) 1192
injection (1189) 1189
phase-ii trial (1171) 1171
glioblastoma (1160) 1160
diabetic retinopathy (1158) 1158
neoplasm staging (1153) 1153
neoplasm metastasis (1146) 1146
antibodies, monoclonal - adverse effects (1120) 1120
abridged index medicus (1110) 1110
phase-ii (1086) 1086
vascular endothelial growth factor a - metabolism (1075) 1075
sense organs (1069) 1069
combined modality therapy (1063) 1063
risk factors (1054) 1054
breast cancer (1044) 1044
studies (1036) 1036
open-label (1030) 1030
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (24313) 24313
German (582) 582
French (541) 541
Japanese (453) 453
Spanish (199) 199
Korean (170) 170
Chinese (169) 169
Russian (74) 74
Turkish (55) 55
Czech (49) 49
Polish (49) 49
Portuguese (47) 47
Hungarian (37) 37
Italian (20) 20
Romanian (13) 13
Dutch (9) 9
Slovenian (8) 8
Finnish (5) 5
Slovak (4) 4
Swedish (4) 4
Croatian (2) 2
Hebrew (2) 2
Arabic (1) 1
Bosnian (1) 1
Icelandic (1) 1
Indonesian (1) 1
Norwegian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature medicine, ISSN 1546-170X, 2018, Volume 24, Issue 6, pp. 749 - 757
We describe results from IMmotion150, a randomized phase 2 study of atezolizumab (anti-PD-L1) alone or combined with bevacizumab (anti-VEGF) versus sunitinib... 
MEDICINE, RESEARCH & EXPERIMENTAL | MULTICENTER | PD-L1 EXPRESSION | BIOCHEMISTRY & MOLECULAR BIOLOGY | PHASE-III | SINGLE-ARM | CANCER | CELL BIOLOGY | PATHWAY | SUPPRESSOR-CELLS | NIVOLUMAB | TUMOR-GROWTH | ENDOTHELIAL GROWTH-FACTOR | Sunitinib - pharmacology | Bevacizumab - pharmacology | Kidney Neoplasms - genetics | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Gene Expression Regulation, Neoplastic | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Gene Expression Profiling | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Aged, 80 and over | Adult | Female | Carcinoma, Renal Cell - drug therapy | Antibodies, Monoclonal - pharmacology | Kaplan-Meier Estimate | Treatment Outcome | Mutation - genetics | Sunitinib - adverse effects | Sunitinib - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Kidney Neoplasms - drug therapy | Development and progression | Dosage and administration | Angiogenesis inhibitors | Carcinoma, Renal cell | Comparative analysis | Drug therapy | Cell survival | Inflammation | Gene expression | Molecular chains | Bevacizumab | Metastases | Confidence intervals | Angiogenesis | Immune checkpoint | Immunotherapy | γ-Interferon | PD-L1 protein | Biomarkers | Vascular endothelial growth factor | Clear cell-type renal cell carcinoma
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 20, pp. 1954 - 1963
The addition of bevacizumab to lomustine in patients with recurrent glioblastoma failed to increase overall survival but was associated with a small increase... 
Medicine(all) | MEDICINE, GENERAL & INTERNAL | METHYLATION | PROGNOSTIC-FACTORS | PLUS IRINOTECAN | SINGLE-AGENT BEVACIZUMAB | RESPONSE ASSESSMENT | CLINICAL-TRIALS | PHASE-2 | QUALITY-OF-LIFE | RADIOTHERAPY | TEMOZOLOMIDE | Bevacizumab - administration & dosage | Bevacizumab - adverse effects | Humans | Lomustine - adverse effects | Middle Aged | Kaplan-Meier Estimate | Male | Antineoplastic Agents, Alkylating - administration & dosage | Brain Neoplasms - drug therapy | Chemoradiotherapy | Glioblastoma - radiotherapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Aged, 80 and over | Adult | Female | Aged | Brain Neoplasms - mortality | Antineoplastic Agents, Alkylating - adverse effects | Brain Neoplasms - radiotherapy | Glioblastoma - drug therapy | Glioblastoma - mortality | Lomustine - administration & dosage | Patient outcomes | Lomustine | Outcome and process assessment (Health Care) | Dosage and administration | Research | Drug therapy | Glioblastoma multiforme | Methods | Medical research | Nuclear magnetic resonance--NMR | Brain cancer | Methylguanine | Glioblastoma | Clinical trials | Oncology | Cognition | Cancer therapies | Survival | Quality of life | Bevacizumab | O6-methylguanine-DNA methyltransferase | Studies | Brain research | DNA methylation | DNA methyltransferase | Cancer
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 10/2018, Volume 2018, Issue 10, p. CD007419
Background Diabetic macular oedema (DMO) is a common complication of diabetic retinopathy. Antiangiogenic therapy with anti‐vascular endothelial growth factor... 
Endocrine & metabolic | Receptors, Vascular Endothelial Growth Factor | Vascular Endothelial Growth Factor A | Macular oedema | Laser Coagulation | Visual Acuity | Retinal disease | Angiogenesis Inhibitors | Recombinant Fusion Proteins | Bevacizumab | Randomized Controlled Trials as Topic | Diabetic eye disease | Aptamers, Nucleotide | Ranibizumab | Quality of Life | Macular Edema | Diabetes | Eyes & vision | Network Meta‐Analysis | Triamcinolone | Medicine General & Introductory Medical Sciences | Diabetic Retinopathy | Retinal disease (including age‐related macular degeneration) | CLINICAL-TRIAL | RANIBIZUMAB PLUS PROMPT | RANDOMIZED CONTROLLED-TRIAL | Receptors, Vascular Endothelial Growth Factor [therapeutic use] | DEFERRED LASER | MEDICINE, GENERAL & INTERNAL | PEGAPTANIB SODIUM | Bevacizumab [adverse effects; therapeutic use] | Laser Coagulation [methods] | Aptamers, Nucleotide [adverse effects; therapeutic use] | Network Meta-Analysis | QUALITY-OF-LIFE | Macular Edema [drug therapy; etiology; surgery] | Vascular Endothelial Growth Factor A [antagonists & inhibitors] | Visual Acuity [drug effects; physiology] | COST-EFFECTIVENESS | Angiogenesis Inhibitors [adverse effects; therapeutic use] | LASER PHOTOCOAGULATION | Ranibizumab [adverse effects; therapeutic use] | Recombinant Fusion Proteins [adverse effects; therapeutic use] | INTRAVITREAL BEVACIZUMAB | Diabetic Retinopathy [complications] | Triamcinolone [adverse effects; therapeutic use] | VEGF TRAP-EYE | Bevacizumab - therapeutic use | Receptors, Vascular Endothelial Growth Factor - therapeutic use | Recombinant Fusion Proteins - adverse effects | Bevacizumab - adverse effects | Humans | Recombinant Fusion Proteins - therapeutic use | Ranibizumab - therapeutic use | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Diabetic Retinopathy - complications | Macular Edema - etiology | Ranibizumab - adverse effects | Visual Acuity - drug effects | Triamcinolone - adverse effects | Laser Coagulation - methods | Angiogenesis Inhibitors - therapeutic use | Angiogenesis Inhibitors - adverse effects | Triamcinolone - therapeutic use | Visual Acuity - physiology | Aptamers, Nucleotide - therapeutic use | Aptamers, Nucleotide - adverse effects | Macular Edema - surgery | Macular Edema - drug therapy
Journal Article
Journal of biomedical materials research. Part A, ISSN 1549-3296, 2015, Volume 103, Issue 10, pp. 3148 - 3156
Journal Article
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 05/2017, Volume 317, Issue 20, pp. 2072 - 2087
Journal Article
Journal Article
Survey of Ophthalmology, ISSN 0039-6257, 2015, Volume 60, Issue 6, pp. 524 - 535
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents
Journal Article